# Metformin Prostate Cancer Adjuvant Trial

> **NCT02176161** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 59 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Recurrent

## Interventions

- **DRUG:** Metformin Hydrochloride Extended Release 750mg

## Key facts

- **NCT ID:** NCT02176161
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2021-07-21
- **Final completion:** 2021-07-21
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176161, "Metformin Prostate Cancer Adjuvant Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02176161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*